Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.
Mannucci, C., Pichini, S., Ventura Spagnolo, E., Calapai, F., Gangemi, S., Navarra, M., et al. (2017). Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence. CURRENT DRUG METABOLISM, 19 [10.2174/1389200219666171207122227].
Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence
Ventura Spagnolo, E;
2017-01-01
Abstract
Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Curr Drag.pdf
Solo gestori archvio
Descrizione: file pdf pre print
Tipologia:
Versione Editoriale
Dimensione
152.69 kB
Formato
Adobe PDF
|
152.69 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
